Why the study?
Anticoagulant management in pregnant women with mechanical heart valves is challenging, with unresolved issues regarding optimal agent selection, target anticoagulation levels, and balancing maternal thrombotic risk against fetal teratogenicity.
What is the optimal management of anticoagulant therapy in pregnant women with mechanical heart valves to balance maternal thrombotic risk and fetal teratogenicity?
Population
Pregnant women with mechanical heart valves
Design
Position paper and consensus document based on a comprehensive literature review
Authors
Loading...
Anticoagulation in pregnant women with MHVs remains high-risk; review leaves open optimal regimens balancing maternal and fetal outcomes.
What is the optimal management of anticoagulant therapy in pregnant women with mechanical heart valves to balance maternal thrombotic risk and fetal teratogenicity?
This FCSA position paper provides expert consensus and practical guidance on balancing maternal thrombotic risks and fetal teratogenic risks when managing anticoagulation in pregnant women with mechanical heart valves.
Campello et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: